Head to Head Review: AnaptysBio (NASDAQ:ANAB) and Oncolytics Biotech (NASDAQ:ONCY)

AnaptysBio (NASDAQ:ANAB) and Oncolytics Biotech (NASDAQ:ONCY) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, risk, analyst recommendations, earnings, dividends, profitability and institutional ownership.

Profitability

This table compares AnaptysBio and Oncolytics Biotech’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
AnaptysBio	-711.17%	-161.40%	-35.07%
Oncolytics Biotech	N/A	-110.66%	-74.28%

Valuation & Earnings

This table compares AnaptysBio and Oncolytics Biotech’s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AnaptysBio	$17.16 million	39.90	-$163.62 million	($6.14)	-4.08
Oncolytics Biotech	N/A	N/A	-$20.56 million	($0.30)	-3.30

Oncolytics Biotech has lower revenue, but higher earnings than AnaptysBio. AnaptysBio is trading at a lower price-to-earnings ratio than Oncolytics Biotech, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

AnaptysBio has a beta of -0.33, meaning that its stock price is 133% less volatile than the S&P 500. Comparatively, Oncolytics Biotech has a beta of 1.87, meaning that its stock price is 87% more volatile than the S&P 500.

Insider & Institutional Ownership

6.8% of Oncolytics Biotech shares are owned by institutional investors. 33.7% of AnaptysBio shares are owned by company insiders. Comparatively, 0.1% of Oncolytics Biotech shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of recent ratings for AnaptysBio and Oncolytics Biotech, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AnaptysBio	0	2	7	0	2.78
Oncolytics Biotech	0	0	3	0	3.00

AnaptysBio currently has a consensus price target of $46.38, indicating a potential upside of 85.06%. Oncolytics Biotech has a consensus price target of $4.00, indicating a potential upside of 304.04%. Given Oncolytics Biotech’s stronger consensus rating and higher possible upside, analysts clearly believe Oncolytics Biotech is more favorable than AnaptysBio.

Summary

Oncolytics Biotech beats AnaptysBio on 9 of the 13 factors compared between the two stocks.

About AnaptysBio

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.

About Oncolytics Biotech

Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep, as well as with Roche Holding AG. The company was incorporated in 1998 and is headquartered in Calgary, Canada.